Search research articles
Contact Us
Filters
Showing results (151-160 of 238) with videos related to
Page
of 24
Sort By:
The Journal of Biological Chemistry
|
July 18, 2001
Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities
B Razani, J A Engelman, X B Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 19, 2018
NOTCH1 Represses MCL-1 Levels in GSI-resistant T-ALL, Making them Susceptible to ABT-263
Anahita Dastur, AHyun Choi, Carlotta Costa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 4, 2013
Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorectal cancer
Erin M Coffee, Anthony C Faber, Jatin Roper, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 12, 2013
Co-clinical trials demonstrate superiority of crizotinib to chemotherapy in ALK-rearranged non-small cell lung cancer and predict strategies to overcome resistance
Zhao Chen, Esra Akbay, Oliver Mikse, et al.
Science Translational Medicine
|
January 27, 2012
Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers
Ryohei Katayama, Alice T Shaw, Tahsin M Khan, et al.
Cancer Discovery
|
March 27, 2012
EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib
Ryan B Corcoran, Hiromichi Ebi, Alexa B Turke, et al.
Cell Reports
|
November 19, 2025
Structural basis of DNA-dependent coactivator recruitment by the tuft cell master regulator POU2F3
Aktan Alpsoy, Jonathan J Ipsaro, Damianos Skopelitis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 5, 2013
ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer
Justin F Gainor, Anna M Varghese, Sai-Hong Ignatius Ou, et al.
Journal of the National Cancer Institute
|
November 9, 2015
Preclinical Efficacy of Ado-trastuzumab Emtansine in the Brain Microenvironment
Vasileios Askoxylakis, Gino B Ferraro, David P Kodack, et al.
Cancer Cell
|
July 9, 2014
CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors
Sadhna R Vora, Dejan Juric, Nayoon Kim, et al.
Page
of 24
Search research articles
Search
Showing results (151-160 of 238) with videos related to
Sort By:
Page
of 24
The Journal of Biological Chemistry
|
July 18, 2001
Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities
B Razani, J A Engelman, X B Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 19, 2018
NOTCH1 Represses MCL-1 Levels in GSI-resistant T-ALL, Making them Susceptible to ABT-263
Anahita Dastur, AHyun Choi, Carlotta Costa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 4, 2013
Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorectal cancer
Erin M Coffee, Anthony C Faber, Jatin Roper, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 12, 2013
Co-clinical trials demonstrate superiority of crizotinib to chemotherapy in ALK-rearranged non-small cell lung cancer and predict strategies to overcome resistance
Zhao Chen, Esra Akbay, Oliver Mikse, et al.
Science Translational Medicine
|
January 27, 2012
Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers
Ryohei Katayama, Alice T Shaw, Tahsin M Khan, et al.
Cancer Discovery
|
March 27, 2012
EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib
Ryan B Corcoran, Hiromichi Ebi, Alexa B Turke, et al.
Cell Reports
|
November 19, 2025
Structural basis of DNA-dependent coactivator recruitment by the tuft cell master regulator POU2F3
Aktan Alpsoy, Jonathan J Ipsaro, Damianos Skopelitis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 5, 2013
ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer
Justin F Gainor, Anna M Varghese, Sai-Hong Ignatius Ou, et al.
Journal of the National Cancer Institute
|
November 9, 2015
Preclinical Efficacy of Ado-trastuzumab Emtansine in the Brain Microenvironment
Vasileios Askoxylakis, Gino B Ferraro, David P Kodack, et al.
Cancer Cell
|
July 9, 2014
CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors
Sadhna R Vora, Dejan Juric, Nayoon Kim, et al.
Page
of 24